Ipek Erdogan-Trinkaus - 12 Jan 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ETON
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jan 2026, 18:05:48 UTC
Prior SEC filing: 12 Dec 2025
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Gruber

Key filing fact

Ipek Erdogan-Trinkaus filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 14 Jan 2026.

Key facts

This page summarizes Ipek Erdogan-Trinkaus's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Jan 2026, 18:05.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002047026 Primary reporting owner

Erdogan-Trinkaus Ipek

Relationship: Chief Commercial Officer
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ James R. Gruber
Signature date: 14 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,655
Change %: +49%
Price: $0.000000
Shares after: 123,878
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,655
Exercise price: $15.47
Footnotes: F1

ETON transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +25,856
Change %: +21%
Price: $0.000000
Shares after: 149,734
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,856
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

Footnote F3

The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

SEC remarks

The signing person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.